Drug Trial Radar · NCT06687941
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Dec 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Aptamer Sciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CHA University; National Cancer Center, Korea; Samsung Medical Center; Severance Hospital
- First posted
- Nov 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
Conditions
- Neoplasms
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Liver Neoplasms
Interventions
AST-201Drug
AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: 4 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
CHA Bundang Medical Center
Seongnam, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
National Cancer Center, Korea
Goyang-si, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.